David S. Moura
YOU?
Author Swipe
View article: Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS)
Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS) Open
Cancers, especially fusion oncoprotein (FO)-driven hematological cancers and sarcomas, often develop from a low number of key mutations. Solitary Fibrous Tumor (SFT) is a rare mesenchymal tumor driven by the NAB2-STAT6 oncofusion gene. Cur…
View article: Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures Open
These findings highlight substantial intratumoral heterogeneity, which may contribute to the variable response to ICI therapy. As immune checkpoint molecule expression influences treatment eligibility, multiple biopsies from different tumo…
View article: O papel dos canabinóides no tratamento dos sintomas não motores na Doença de Parkinson
O papel dos canabinóides no tratamento dos sintomas não motores na Doença de Parkinson Open
A doença de Parkinson (DP) é uma doença manifestada pela degeneração progressiva de neurónios dopaminérgicos nos gânglios basais. Os sintomas não-motores (SNM), tais como perturbações do sono, declínio cognitivo, ansiedade, depressão, psic…
View article: Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma Open
Undifferentiated pleomorphic sarcoma (UPS) is a rare cancer with limited systemic treatment options and poor outcomes. To seek novel therapeutic interventions, we undertook mutational analysis of 20 UPS patient tumours, four established UP…
View article: Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS)
Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS) Open
Cancers, especially fusion oncoprotein (FO)-driven hematological cancers and sarcomas, often develop from a low number of key mutations. Solitary Fibrous Tumor (SFT) is a rare mesenchymal tumor driven by the NAB2-STAT6 oncofusion gene. Cur…
View article: 84P Exploring BET inhibitors as promising agents for solitary fibrous tumor
84P Exploring BET inhibitors as promising agents for solitary fibrous tumor Open
View article: Preclinical models of soft tissue sarcomas – generation and applications to enhance translational research
Preclinical models of soft tissue sarcomas – generation and applications to enhance translational research Open
Soft tissue sarcomas (STS) represent a large group of rare and ultra-rare tumors distinguished by unique morphological, molecular and clinical features. Patients with such rare cancers are generally underrepresented in clinical trials whic…
View article: Supplementary Table S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S1. Univariate analysis of cell densities.
View article: Supplementary Figure S5 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S5 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S5. CXCL10 protein expression in cell culture supernatant. The expression levels of CXCL10 soluble protein were measured after anti-CD3/CD28 stimulation and anti-PD-1 treatment in PBMC cultures (A) and tumor multi-cult…
View article: Supplementary Table S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S4. MAXSTAT cut-off calculated for the Δ of gene expression between week 13 and baseline samples.
View article: Data from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Data from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Purpose:The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial.Experi…
View article: Supplementary Figure S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S4. Correlation between progression-free survival (PFS) and the dynamic alteration in the expression of additional soluble proteins in plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). PF…
View article: Supplementary Figure S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S3. Dynamic modulation of soluble factors in paired plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). Significance was defined as p<0.05 and calculated by Wilcoxon paired test. Concentrat…
View article: Supplementary Figure S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S2. Correlation between progression-free survival (PFS) and the dynamic increase in cytologic markers. A) CD3; B) CD4; C) CD8; D) CD20; E) CD66b; F) CD68 and G) CD138. PFS cut-off was defined as 9.4 months and calculat…
View article: Supplementary Table S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S3. Univariate analysis of the dynamic (Δ) alteration in the expression levels of genes modulated by treatment.
View article: Supplementary Table S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Table S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Table S2. Dynamic gene expression between baseline and week 13.
View article: Supplementary Figure S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Supplementary Figure S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial Open
Supplementary Figure S1. Consort diagram. Number of samples included in the correlative studies of HTG transcriptomics, multiplexed immunoassays and multiplexed immune-phenotyping.
View article: Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial Open
Background Herein, we present the results of the phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS). Methods Progressing patients with a diagnosis of BS were eli…
View article: Supplementary Table S4 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S4 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
Pathway over-representation analysis for REDSARC genes
View article: Supplementary Table S7 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S7 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
List of significant genes of REDSARC-refined gene signature
View article: Supplementary Table S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
Baseline demographic characteristics in ANNOUNCE
View article: Supplementary Table S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
Baseline demographic characteristics in ANNOUNCE
View article: Supplementary Table S6 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S6 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
Clinical and pathologic characteristics: GEIS vs. ANNOUNCE
View article: Supplementary Table S3 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S3 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
A). The association of molecular subtypes (CC1, CC2, and CC3) with histologic subtype, metastatic site (lung/liver), and tumor grade. B).Tumor responses in different molecular subtypes (CC1, CC2, and CC3). C).Tumor responses by treatment a…
View article: Supplementary Table S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
ANNOUNCE REDSARC centroids
View article: Supplementary Figure S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Figure S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
Expression biomarker ESR1. (A) Boxplot shows the significant subtype difference of ESR1 expression in uterine leiomyosarcoma tumors (P = 0.00014). (B, C) Kaplan-Meier plots show patients with uterine leiomyosarcoma in CC3 had longer (B) PF…
View article: Supplementary Table S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
ANNOUNCE REDSARC centroids
View article: Supplementary Figure S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Figure S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
Identification of three soft tissue sarcoma subtypes. (A) REMARK (Reporting Recommendation for Tumor Marker Prognostic Studies) diagram for patients in the ANNOUNCE trial. (B) Consensus clustering matrix of 259 samples for k = 2 to k = 5 a…
View article: Supplementary Table S3 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S3 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
A). The association of molecular subtypes (CC1, CC2, and CC3) with histologic subtype, metastatic site (lung/liver), and tumor grade. B).Tumor responses in different molecular subtypes (CC1, CC2, and CC3). C).Tumor responses by treatment a…
View article: Supplementary Table S7 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Supplementary Table S7 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE Open
List of significant genes of REDSARC-refined gene signature